Justin Brotten

ASCO Breakthrough, Singapore 2026: Advances in p53-Targeted Therapies

The first important progress in targeting p53 mutations happened in the 1980s and 1990s when...

Clinical Trial Updates: Is Now the Appropriate Time to Consider Clinical Trial Matching?

(Discussions at ASCO Breakthrough, Singapore 2026) Translating clinical knowledge into effective bedside care means turning...

The future (Off the Shelf) of Cancer Vaccines building on the Past (Personalized)

The future (Off the Shelf) of Cancer Vaccines building on the Past (Personalized) (influenced by...

ASCO Breakthrough 2026 take Home #2

Multi-Cancer Early Detection Testing May Be Effective in a Routine Clinical Setting in ASIA The...

ASCO Breakthrough: SINGAPORE Take Home # 1

Biomarkers are measurable biological signs in your body, such as blood pressure, blood sugar, or...

HubXchange is Back in Bay Area September 2026

Join me at the HubXchange Days in the Bay Area in September 2026 hubXchange is...

Limitations of a Universal Approach to RNA Delivery, One Size Does not Fit All

Naked RNA cannot bind to the cell surface for delivery. Its size and negative charge...

Regulatory CMC

My industry-focused career began at Genentech; here is some of the work I did there....

I’m Attending ASCO Breakthrough 2026 in Singapore!

I’m Attending ASCO Breakthrough 2026 in Singapore! I am pleased to announce that I will...